ThuliumV1, Pascal, Corpus, bibRecord, 000164

Comparison of 120-200 W 2 μm Thulium: Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate

Identifieur interne : 000164 ( Pascal/Corpus ); précédent : 000163; suivant : 000165

Comparison of 120-200 W 2 μm Thulium: Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate

Auteurs : Christopher Netsch ; Thorsten Bach ; Laura Pohlmann ; Thomas Herrmann ; Andreas J. Gross

Source :

Journal of endourology [ 0892-7790 ] ; 2012.

RBID : Pascal:12-0145651

Descripteurs français

Pascal (Inist)
- Etude comparative, Thulium, Yttrium, Prostate, Néphrologie, Urologie.

English descriptors

KwdEn :
- Comparative study, Nephrology, Prostate, Thulium, Urology, Yttrium.

Abstract

Purpose: To evaluate efficacy and safety of 200 W 2 μm thulium:yttrium-aluminum-garnet vapoenucleation of the prostate (ThuVEP) for patients with benign prostatic obstruction (BPO). Patients and Methods: Twenty-eight consecutive patients with symptomatic BPO were treated with 200 W ThuVEP. Patients were matched for age and preoperative prostate volume with 28 patients from our 120 W ThuVEP database. Patient data and postoperative outcome at 12-month follow-up were compared. Results: Mean prostate volume (65.39 vs 68.62 cc) and resected weight (40.72 vs 53.18 g) differed not significantly between 200 and 120 W ThuVEP. The percentage of resected tissue was lower with 200 W compared with 120 W (58.48 vs 72.93%, P=0.047) because of the higher rate of ablated tissue. There were no differences in mean operative (69.21 vs 78.67 min), laser (45.43 vs 48.58 min), morcellation (16.52 vs 20.48 min), and catheter (2.2 vs 2.1 d) time between the devices. Three patients needed immediate re-treatment (hemorrhage necessitating coagulation 1=200 W, secondary apical resection 2 120/200 W). One (1.79%) patient (120 W) needed a blood transfusion postoperatively. Fifty-one (91%) patients completed 12-month follow-up. Quality of life, International Prostate Symptom Score, peak urinary flow rate, postvoid residual urine, prostate-specific antigen level, and prostate volume improved significantly (P≤0.019) and were not different between the devices. At follow-up, two (3.57%) patients (120/200 W) had a bladder neck contracture. Conclusions: ThuVEP is a safe and efficacious procedure for patients with symptomatic BPO. 120 and 200 W ThuVEP had an equivalent clinical outcome at 12-month follow-up.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0892-7790`
A03		`1`		`@0 J. endourol.`
A05				`@2 26`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Comparison of 120-200 W 2 μm Thulium: Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate`
A11	`01`	`1`		`@1 NETSCH (Christopher)`
A11	`02`	`1`		`@1 BACH (Thorsten)`
A11	`03`	`1`		`@1 POHLMANN (Laura)`
A11	`04`	`1`		`@1 HERRMANN (Thomas)`
A11	`05`	`1`		`@1 GROSS (Andreas J.)`
A14	`01`			`@1 Department of Urology, Asklepios Hospital Barmbek @2 Hamburg @3 DEU @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut.`
A14	`02`			`@1 MHH Medical School of Hannover, Department of Urology @2 Hannover @3 DEU @Z 4 aut.`
A20				`@1 224-229`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 21584 @5 354000509208010040`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 26 ref.`
A47	`01`	`1`		`@0 12-0145651`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of endourology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Purpose: To evaluate efficacy and safety of 200 W 2 μm thulium:yttrium-aluminum-garnet vapoenucleation of the prostate (ThuVEP) for patients with benign prostatic obstruction (BPO). Patients and Methods: Twenty-eight consecutive patients with symptomatic BPO were treated with 200 W ThuVEP. Patients were matched for age and preoperative prostate volume with 28 patients from our 120 W ThuVEP database. Patient data and postoperative outcome at 12-month follow-up were compared. Results: Mean prostate volume (65.39 vs 68.62 cc) and resected weight (40.72 vs 53.18 g) differed not significantly between 200 and 120 W ThuVEP. The percentage of resected tissue was lower with 200 W compared with 120 W (58.48 vs 72.93%, P=0.047) because of the higher rate of ablated tissue. There were no differences in mean operative (69.21 vs 78.67 min), laser (45.43 vs 48.58 min), morcellation (16.52 vs 20.48 min), and catheter (2.2 vs 2.1 d) time between the devices. Three patients needed immediate re-treatment (hemorrhage necessitating coagulation 1=200 W, secondary apical resection 2 120/200 W). One (1.79%) patient (120 W) needed a blood transfusion postoperatively. Fifty-one (91%) patients completed 12-month follow-up. Quality of life, International Prostate Symptom Score, peak urinary flow rate, postvoid residual urine, prostate-specific antigen level, and prostate volume improved significantly (P≤0.019) and were not different between the devices. At follow-up, two (3.57%) patients (120/200 W) had a bladder neck contracture. Conclusions: ThuVEP is a safe and efficacious procedure for patients with symptomatic BPO. 120 and 200 W ThuVEP had an equivalent clinical outcome at 12-month follow-up.
C02	`01`	`X`		`@0 002B14`
C03	`01`	`X`	`FRE`	`@0 Etude comparative @5 02`
C03	`01`	`X`	`ENG`	`@0 Comparative study @5 02`
C03	`01`	`X`	`SPA`	`@0 Estudio comparativo @5 02`
C03	`02`	`X`	`FRE`	`@0 Thulium @2 NC @5 03`
C03	`02`	`X`	`ENG`	`@0 Thulium @2 NC @5 03`
C03	`02`	`X`	`SPA`	`@0 Tulio @2 NC @5 03`
C03	`03`	`X`	`FRE`	`@0 Yttrium @2 NC @5 05`
C03	`03`	`X`	`ENG`	`@0 Yttrium @2 NC @5 05`
C03	`03`	`X`	`SPA`	`@0 Ytrio @2 NC @5 05`
C03	`04`	`X`	`FRE`	`@0 Prostate @5 06`
C03	`04`	`X`	`ENG`	`@0 Prostate @5 06`
C03	`04`	`X`	`SPA`	`@0 Prostata @5 06`
C03	`05`	`X`	`FRE`	`@0 Néphrologie @5 08`
C03	`05`	`X`	`ENG`	`@0 Nephrology @5 08`
C03	`05`	`X`	`SPA`	`@0 Nefrología @5 08`
C03	`06`	`X`	`FRE`	`@0 Urologie @5 09`
C03	`06`	`X`	`ENG`	`@0 Urology @5 09`
C03	`06`	`X`	`SPA`	`@0 Urología @5 09`
C07	`01`	`X`	`FRE`	`@0 Appareil urogénital @5 37`
C07	`01`	`X`	`ENG`	`@0 Urogenital system @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato urogenital @5 37`
N21				`@1 114`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0145651 INIST
ET :	Comparison of 120-200 W 2 μm Thulium: Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate
AU :	NETSCH (Christopher); BACH (Thorsten); POHLMANN (Laura); HERRMANN (Thomas); GROSS (Andreas J.)
AF :	Department of Urology, Asklepios Hospital Barmbek/Hamburg/Allemagne (1 aut., 2 aut., 3 aut., 5 aut.); MHH Medical School of Hannover, Department of Urology/Hannover/Allemagne (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of endourology; ISSN 0892-7790; Etats-Unis; Da. 2012; Vol. 26; No. 3; Pp. 224-229; Bibl. 26 ref.
LA :	Anglais
EA :	Purpose: To evaluate efficacy and safety of 200 W 2 μm thulium:yttrium-aluminum-garnet vapoenucleation of the prostate (ThuVEP) for patients with benign prostatic obstruction (BPO). Patients and Methods: Twenty-eight consecutive patients with symptomatic BPO were treated with 200 W ThuVEP. Patients were matched for age and preoperative prostate volume with 28 patients from our 120 W ThuVEP database. Patient data and postoperative outcome at 12-month follow-up were compared. Results: Mean prostate volume (65.39 vs 68.62 cc) and resected weight (40.72 vs 53.18 g) differed not significantly between 200 and 120 W ThuVEP. The percentage of resected tissue was lower with 200 W compared with 120 W (58.48 vs 72.93%, P=0.047) because of the higher rate of ablated tissue. There were no differences in mean operative (69.21 vs 78.67 min), laser (45.43 vs 48.58 min), morcellation (16.52 vs 20.48 min), and catheter (2.2 vs 2.1 d) time between the devices. Three patients needed immediate re-treatment (hemorrhage necessitating coagulation 1=200 W, secondary apical resection 2 120/200 W). One (1.79%) patient (120 W) needed a blood transfusion postoperatively. Fifty-one (91%) patients completed 12-month follow-up. Quality of life, International Prostate Symptom Score, peak urinary flow rate, postvoid residual urine, prostate-specific antigen level, and prostate volume improved significantly (P≤0.019) and were not different between the devices. At follow-up, two (3.57%) patients (120/200 W) had a bladder neck contracture. Conclusions: ThuVEP is a safe and efficacious procedure for patients with symptomatic BPO. 120 and 200 W ThuVEP had an equivalent clinical outcome at 12-month follow-up.
CC :	002B14
FD :	Etude comparative; Thulium; Yttrium; Prostate; Néphrologie; Urologie
FG :	Appareil urogénital
ED :	Comparative study; Thulium; Yttrium; Prostate; Nephrology; Urology
EG :	Urogenital system
SD :	Estudio comparativo; Tulio; Ytrio; Prostata; Nefrología; Urología
LO :	INIST-21584.354000509208010040
ID :	12-0145651

Links to Exploration step

Pascal:12-0145651

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparison of 120-200 W 2 μm Thulium: Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate</title>
<author><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pohlmann, Laura" sort="Pohlmann, Laura" uniqKey="Pohlmann L" first="Laura" last="Pohlmann">Laura Pohlmann</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Herrmann, Thomas" sort="Herrmann, Thomas" uniqKey="Herrmann T" first="Thomas" last="Herrmann">Thomas Herrmann</name>
<affiliation><inist:fA14 i1="02"><s1>MHH Medical School of Hannover, Department of Urology</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J." last="Gross">Andreas J. Gross</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0145651</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0145651 INIST</idno>
<idno type="RBID">Pascal:12-0145651</idno>
<idno type="wicri:Area/Pascal/Corpus">000164</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparison of 120-200 W 2 μm Thulium: Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate</title>
<author><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pohlmann, Laura" sort="Pohlmann, Laura" uniqKey="Pohlmann L" first="Laura" last="Pohlmann">Laura Pohlmann</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Herrmann, Thomas" sort="Herrmann, Thomas" uniqKey="Herrmann T" first="Thomas" last="Herrmann">Thomas Herrmann</name>
<affiliation><inist:fA14 i1="02"><s1>MHH Medical School of Hannover, Department of Urology</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J." last="Gross">Andreas J. Gross</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of endourology</title>
<title level="j" type="abbreviated">J. endourol.</title>
<idno type="ISSN">0892-7790</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of endourology</title>
<title level="j" type="abbreviated">J. endourol.</title>
<idno type="ISSN">0892-7790</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Comparative study</term>
<term>Nephrology</term>
<term>Prostate</term>
<term>Thulium</term>
<term>Urology</term>
<term>Yttrium</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Etude comparative</term>
<term>Thulium</term>
<term>Yttrium</term>
<term>Prostate</term>
<term>Néphrologie</term>
<term>Urologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose: To evaluate efficacy and safety of 200 W 2 μm thulium:yttrium-aluminum-garnet vapoenucleation of the prostate (ThuVEP) for patients with benign prostatic obstruction (BPO). Patients and Methods: Twenty-eight consecutive patients with symptomatic BPO were treated with 200 W ThuVEP. Patients were matched for age and preoperative prostate volume with 28 patients from our 120 W ThuVEP database. Patient data and postoperative outcome at 12-month follow-up were compared. Results: Mean prostate volume (65.39 vs 68.62 cc) and resected weight (40.72 vs 53.18 g) differed not significantly between 200 and 120 W ThuVEP. The percentage of resected tissue was lower with 200 W compared with 120 W (58.48 vs 72.93%, P=0.047) because of the higher rate of ablated tissue. There were no differences in mean operative (69.21 vs 78.67 min), laser (45.43 vs 48.58 min), morcellation (16.52 vs 20.48 min), and catheter (2.2 vs 2.1 d) time between the devices. Three patients needed immediate re-treatment (hemorrhage necessitating coagulation 1=200 W, secondary apical resection 2 120/200 W). One (1.79%) patient (120 W) needed a blood transfusion postoperatively. Fifty-one (91%) patients completed 12-month follow-up. Quality of life, International Prostate Symptom Score, peak urinary flow rate, postvoid residual urine, prostate-specific antigen level, and prostate volume improved significantly (P≤0.019) and were not different between the devices. At follow-up, two (3.57%) patients (120/200 W) had a bladder neck contracture. Conclusions: ThuVEP is a safe and efficacious procedure for patients with symptomatic BPO. 120 and 200 W ThuVEP had an equivalent clinical outcome at 12-month follow-up.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0892-7790</s0>
</fA01>
<fA03 i2="1"><s0>J. endourol.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Comparison of 120-200 W 2 μm Thulium: Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>NETSCH (Christopher)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BACH (Thorsten)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>POHLMANN (Laura)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HERRMANN (Thomas)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GROSS (Andreas J.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>MHH Medical School of Hannover, Department of Urology</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>224-229</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>21584</s2>
<s5>354000509208010040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>26 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0145651</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of endourology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Purpose: To evaluate efficacy and safety of 200 W 2 μm thulium:yttrium-aluminum-garnet vapoenucleation of the prostate (ThuVEP) for patients with benign prostatic obstruction (BPO). Patients and Methods: Twenty-eight consecutive patients with symptomatic BPO were treated with 200 W ThuVEP. Patients were matched for age and preoperative prostate volume with 28 patients from our 120 W ThuVEP database. Patient data and postoperative outcome at 12-month follow-up were compared. Results: Mean prostate volume (65.39 vs 68.62 cc) and resected weight (40.72 vs 53.18 g) differed not significantly between 200 and 120 W ThuVEP. The percentage of resected tissue was lower with 200 W compared with 120 W (58.48 vs 72.93%, P=0.047) because of the higher rate of ablated tissue. There were no differences in mean operative (69.21 vs 78.67 min), laser (45.43 vs 48.58 min), morcellation (16.52 vs 20.48 min), and catheter (2.2 vs 2.1 d) time between the devices. Three patients needed immediate re-treatment (hemorrhage necessitating coagulation 1=200 W, secondary apical resection 2 120/200 W). One (1.79%) patient (120 W) needed a blood transfusion postoperatively. Fifty-one (91%) patients completed 12-month follow-up. Quality of life, International Prostate Symptom Score, peak urinary flow rate, postvoid residual urine, prostate-specific antigen level, and prostate volume improved significantly (P≤0.019) and were not different between the devices. At follow-up, two (3.57%) patients (120/200 W) had a bladder neck contracture. Conclusions: ThuVEP is a safe and efficacious procedure for patients with symptomatic BPO. 120 and 200 W ThuVEP had an equivalent clinical outcome at 12-month follow-up.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B14</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Thulium</s0>
<s2>NC</s2>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Thulium</s0>
<s2>NC</s2>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tulio</s0>
<s2>NC</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Yttrium</s0>
<s2>NC</s2>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Yttrium</s0>
<s2>NC</s2>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Ytrio</s0>
<s2>NC</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prostate</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prostate</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Prostata</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Néphrologie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nephrology</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Nefrología</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Urologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Urology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Urología</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil urogénital</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Urogenital system</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato urogenital</s0>
<s5>37</s5>
</fC07>
<fN21><s1>114</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0145651 INIST</NO>
<ET>Comparison of 120-200 W 2 μm Thulium: Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate</ET>
<AU>NETSCH (Christopher); BACH (Thorsten); POHLMANN (Laura); HERRMANN (Thomas); GROSS (Andreas J.)</AU>
<AF>Department of Urology, Asklepios Hospital Barmbek/Hamburg/Allemagne (1 aut., 2 aut., 3 aut., 5 aut.); MHH Medical School of Hannover, Department of Urology/Hannover/Allemagne (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of endourology; ISSN 0892-7790; Etats-Unis; Da. 2012; Vol. 26; No. 3; Pp. 224-229; Bibl. 26 ref.</SO>
<LA>Anglais</LA>
<EA>Purpose: To evaluate efficacy and safety of 200 W 2 μm thulium:yttrium-aluminum-garnet vapoenucleation of the prostate (ThuVEP) for patients with benign prostatic obstruction (BPO). Patients and Methods: Twenty-eight consecutive patients with symptomatic BPO were treated with 200 W ThuVEP. Patients were matched for age and preoperative prostate volume with 28 patients from our 120 W ThuVEP database. Patient data and postoperative outcome at 12-month follow-up were compared. Results: Mean prostate volume (65.39 vs 68.62 cc) and resected weight (40.72 vs 53.18 g) differed not significantly between 200 and 120 W ThuVEP. The percentage of resected tissue was lower with 200 W compared with 120 W (58.48 vs 72.93%, P=0.047) because of the higher rate of ablated tissue. There were no differences in mean operative (69.21 vs 78.67 min), laser (45.43 vs 48.58 min), morcellation (16.52 vs 20.48 min), and catheter (2.2 vs 2.1 d) time between the devices. Three patients needed immediate re-treatment (hemorrhage necessitating coagulation 1=200 W, secondary apical resection 2 120/200 W). One (1.79%) patient (120 W) needed a blood transfusion postoperatively. Fifty-one (91%) patients completed 12-month follow-up. Quality of life, International Prostate Symptom Score, peak urinary flow rate, postvoid residual urine, prostate-specific antigen level, and prostate volume improved significantly (P≤0.019) and were not different between the devices. At follow-up, two (3.57%) patients (120/200 W) had a bladder neck contracture. Conclusions: ThuVEP is a safe and efficacious procedure for patients with symptomatic BPO. 120 and 200 W ThuVEP had an equivalent clinical outcome at 12-month follow-up.</EA>
<CC>002B14</CC>
<FD>Etude comparative; Thulium; Yttrium; Prostate; Néphrologie; Urologie</FD>
<FG>Appareil urogénital</FG>
<ED>Comparative study; Thulium; Yttrium; Prostate; Nephrology; Urology</ED>
<EG>Urogenital system</EG>
<SD>Estudio comparativo; Tulio; Ytrio; Prostata; Nefrología; Urología</SD>
<LO>INIST-21584.354000509208010040</LO>
<ID>12-0145651</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/Pascal/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000164 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pascal/Corpus/biblio.hfd -nk 000164 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Terre
   |area=    ThuliumV1
   |flux=    Pascal
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0145651
   |texte=   Comparison of 120-200 W 2 μm Thulium: Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate
}}

This area was generated with Dilib version V0.6.21.
Data generation: Thu May 12 08:27:09 2016. Site generation: Thu Mar 7 22:33:44 2024

	Serveur d'exploration sur le thulium
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le thulium

Comparison of 120-200 W 2 μm Thulium: Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate

Comparison of 120-200 W 2 μm Thulium: Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri